



Inclisiran

Revised: September 19, 2022.

CASRN: 1639324-58-5

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of inclisiran during breastfeeding. Because inclisiran is a large oligonucleotide, the amount in milk is likely to be very low and absorption by the infant is probably minimal. If inclisiran is required by the mother, it is not a reason to discontinue breastfeeding. Until more data become available, inclisiran should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Cholestyramine, Colesevelam, Colestipol

Substance Identification

Substance Name

Inclisiran

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

CAS Registry Number

1639324-58-5

Drug Class

Breast Feeding

Lactation

Milk, Human

Anticholesteremic Agents

Antilipemic Agents